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WAF1/CIP1
(p21) in mice increases renal proximal tubular cell death and enhances sensitivity to acute renal failure produced by the chemotherapeutic agent cisplatin. We used primary cultures of mouse renal proximal tubular cells (MPTC) grown in optimized culture conditions to investigate the cellular basis for increased apoptosis in p21 knockout mice. Cisplatin (15 M) activated caspase-3 but not caspase-8 or caspase-9 and produced phosphatidylserine externalization, chromatin condensation, and nuclear fragmentation in wild-type [p21(ϩ/ϩ)] MPTC. Caspase-3 activation and apoptosis were accelerated in cisplatin-treated MPTC lacking p21 [p21(Ϫ/Ϫ) MPTC]. In contrast to p21(ϩ/ϩ) MPTC, cisplatin activated caspase-9 but not caspase-8 in p21(Ϫ/Ϫ) MPTC before caspase-3 activation. The caspase-3 inhibitor Asp-Glu-Val-Asp-fluoromethylketone (DEVD-fmk) inhibited caspase-3 activity but did not abolish apoptosis in p21(ϩ/ϩ) and p21(Ϫ/Ϫ) MPTC. General caspase inhibitor Z-Val-Ala-Asp(OCH3)-fluoromethylketone (ZVADfmk) inhibited caspase activity and decreased chromatin condensation by 51% in p21(Ϫ/Ϫ) but not in p21(ϩ/ϩ) MPTC. However, cisplatin-induced phosphatidylserine externalization was not inhibited by ZVAD-fmk in p21(Ϫ/Ϫ) MPTC. We conclude that 1) in the presence of p21, cisplatin activates caspase-3 through a mechanism independent of caspase-8 or caspase-9; 2) in the absence of p21, caspase-9 activation precedes caspase-3 activation; 3) the lack of p21 accelerates caspase-3 activation and cisplatin-induced MPTC apoptosis; and 4) MPTC apoptosis is caspase independent in the presence of p21 but partially dependent on caspases in the absence of p21.
renal proximal tubular cells; caspase activation; DNA damage; knockout mice CISPLATIN IS A WIDELY USED anticancer agent in the treatment of many solid tumors and metastatic cancers (6, 19) . Cisplatin administration causes cell-cycle arrest at different phases of the cell cycle and induces apoptosis in a variety of cancer cells (6) . The major disadvantage of this antineoplastic agent is a dose-dependent and cumulative nephrotoxicity, which manifests primarily as proximal tubule morphological damage (oncosis and apoptosis) and physiological dysfunction (1, 3, 8, 10, 20, 21, 30, 38, 45) . Multiple mechanisms have been implicated in cisplatin-induced nephrotoxicity, including inhibition of protein synthesis, DNA damage, oxidative stress, mitochondrial dysfunction, and alterations in signal transduction pathways involved in apoptosis (12, 17, 36, 39, 41, 45, 48) . Lower concentrations of cisplatin induce apoptosis, whereas concentrations Ͼ50 M cause oncosis in renal proximal tubular cells (7, 25) . Cisplatin-induced apoptosis in this cell type is preceded by activation of caspase-3, but not caspase-1 (3, 4, 8, 32, 44, 48) , and is prevented by bcl-2 (48) . Activation of caspase-8 and caspase-9 by cisplatin has been reported in the LLC-PK 1 cell line (14) .
The cyclin-dependent kinase inhibitor p21
plays a pivotal role in cell differentiation, DNA repair, and apoptosis through regulation of the cell cycle. The p21 WAF1/CIP1 protein is constitutively present at low levels in the nucleus of most cells as a complex with cyclin, cyclin-dependent kinase, and proliferating cell nuclear antigen (23, 49) . p21 WAF1/CIP1 is known to be a mediator of p53 tumor suppressor function and has been implicated in apoptosis caused by numerous agents. DNA damage caused by radiation and various chemotherapeutic drugs activates p53, which upregulates p21 WAF1/CIP1 mRNA and protein levels. Induction of p21 WAF1/CIP1 is required for the p53-dependent arrest in the G 1 phase of the cell cycle after DNA damage (2, 46) . However, transcriptional and posttranscriptional changes in p21 WAF1/CIP1 expression after DNA damage can also be induced in a p53-independent manner (11, 29) . p21 WAF1/CIP1 has differential effects on the sensitivity of cancer cells to ionizing radiation, cisplatin, and other antineoplastic agents, such as adriamycin, taxol, and vincristine, protecting against cell death in some models and not in others (7, 8, 37) . For example, increased levels of p21 WAF1/CIP1 enhance sensitivity of hepatoma and osteosarcoma cells to cisplatin (22) . In contrast, in colon cancer and embryonic fibroblast cells, increased sensitivity to cisplatin and other chemotherapeutic agents is associated with the lack of p21 WAF1/CIP1 (7, 37) . p21 WAF1/CIP1 is rapidly induced in the murine kidney in response to acute renal failure (ARF) produced by ischemia-reperfusion, ureteral obstruction, and cisplatin (29) . The p21 WAF1/CIP1 induction decreases renal damage after cisplatin-and ischemia-induced ARF in murine models (26, 28) . In contrast, the lack of the p21 WAF1/CIP1 gene accelerates progression to ARF and chronic renal failure, increases morphological and functional damage to proximal tubular cells and the kidney, and results in a higher mortality rate (26) (27) (28) . The mechanisms of the protective effects of p21 WAF1/ CIP1 are not clear. It was shown that cells having DNA damaged by cisplatin administration enter the cell cycle, but cell-cycle progression is inhibited in the presence of p21 WAF1/CIP1 . In contrast, kidney cells lacking p21 WAF1/CIP1 progress from the G 1 to S phase of the cell cycle after cisplatin-induced damage (28) . Therefore, it has been proposed that p21 WAF1/CIP1 decreases cisplatin nephrotoxicity by decreasing the number of injured cells that enter the cell cycle and undergo mitosis with damaged DNA, which results in cell death by either apoptosis or oncosis (28) .
The aim of this study was to examine the cellular basis for increased cell death in p21 WAF1/CIP1 knockout mice by investigating the temporal activation and the role of caspase-3, caspase-8, and caspase-9 during cisplatin-induced apoptosis in mouse renal proximal tubular cells (MPTC) obtained from p21 WAF1/CIP1 knockout and wild-type mice.
MATERIALS AND METHODS

Materials.
Cell isolation media, cell culture media, horse serum, and soybean trypsin inhibitor were supplied by Life Technologies (Grand Island, NY). Collagenase type 4 and L-ascorbic acid-2-phosphate magnesium salt were provided by Worthington Biochemical (Freehold, NJ) and Wako BioProducts (Richmond, VA), respectively. Cisplatin [cis-diamminedichloroplatinum(II)], Percoll, methyl ␣-D-glucopyranoside, propidium iodide, and cell culture hormones were purchased from Sigma (St. Louis, MO). Ethidium homodimer and 4Ј,6-diamidino-2-phenylindole dihydrochloride (DAPI) were obtained from Molecular Probes (Eugene, OR). 14 C]glucopyranoside (MGP; specific activity 230 mCi/mmol) was purchased from Amersham Pharmacia Biotech (Piscataway, NJ). The sources of the other reagents have been described previously (34 Isolation of proximal tubules. Mouse renal proximal tubules were isolated by a modification of the method described by Sheridan et al. (40) . The basal isolation medium was Hanks' solution and a 50:50 mixture of DMEM and Ham's F-12 nutrient mix (DMEM/F-12) supplemented with 29 mM NaHCO3, 15 mM HEPES, and penicillin G (150 U/ml). The medium was adjusted to pH 7.4 while being gassed with 95% O2-5% CO2 and was diluted to 295 mosmol/kgH2O before filter sterilization.
The animals were anesthetized with halothane, and both kidneys were removed, dissected under sterile conditions, and placed in ice-cold Hanks' solution gassed with 95% O2-5% CO2. Cortical tissue was removed, placed in fresh ice-cold Hanks' solution, and finely minced with a scalpel blade. Minced tissue was incubated for 30 min at 37°C (with shaking) in digestion medium consisting of Hanks' solution, collagenase type 4 (140 U/ml), and soybean trypsin inhibitor (0.75 mg/ml). Large undigested fragments of cortical tissue were separated by gravity after the mixing of equal volumes of the tissue suspension and ice-cold 10% horse serum in Hanks' solution. Following sedimentation of undigested tissue, the supernatant containing cortical tubules was collected and centrifuged for 2 min ϫ 50 g at 4°C. The pellet was washed with ice-cold Hanks' solution, centrifuged for 2 min ϫ 50 g at 4°C, washed again with DMEM/F-12, centrifuged, and resuspended in DMEM/F-12 medium. Cortical tubules were purified by gradient centrifugation in a 40% Percoll/60% DMEM/F-12 at 36,000 g ϫ 20 min at 4°C. The band containing renal proximal tubules was collected and washed twice with DMEM/F-12, and the final pellet was resuspended in DMEM/F-12.
Culture conditions. The culture medium was a 50:50 mixture of DMEM/F-12 nutrient mix without phenol red and pyruvate, supplemented with 15 mM NaHCO3, 15 mM HEPES, 1 mM glucose, and 5 mM lactate (pH 7.4, 295 mosmol/kgH2O). Renal proximal tubule segments were plated in 35-mm culture dishes (0.3 mg protein/dish) and grown in optimized conditions as described previously for rabbit renal proximal tubular cells (34) . Culture dishes were constantly swirled on an orbital shaker to improve media oxygenation. Human transferrin (5 g/ml), selenium (5 ng/ ml), hydrocortisone (50 nM), bovine insulin (5 g/ml), and L-ascorbic acid-2-phosphate (50 M) were added to the medium immediately before daily media change (2 ml/dish).
O2 consumption. Confluent MPTC monolayers were gently detached from the dishes with a rubber policeman, suspended in 37°C culture medium, and transferred to the O2 consumption (QO2) measurement chamber. QO2 was measured polarographically using a Clark-type electrode as described previously (33, 34). Uncoupled QO2 was used as a marker of the activity of electron transfer through the respiratory chain and was measured after addition of carbonyl cyanide p-(trifluoromethoxy)phenylhydrazone (2 M).
Active Na ϩ transport. Ouabain-sensitive QO2 was used as a marker of active Na ϩ transport as described previously (33). Ouabain-sensitive QO2 was measured in the presence of 1 mM ouabain and calculated as a difference between basal and ouabain-insensitive QO2.
Na
ϩ -dependent glucose uptake. Glucose uptake was assessed using a nonmetabolizable glucose analog, MGP, as described previously (34) . In brief, confluent monolayers of MPTC were washed with 37°C glucose-free culture medium and incubated (with shaking) in glucose-free medium containing 1 mM MGP and 0.2 Ci/ml of [ 14 C]MGP for 30 min at 37°C in a 5% CO 2-95% air atmosphere. Following washing, the amount of [
14 C]MGP associated with the renal proximal tubular cell monolayer was determined by liquid scintillation spectrometry.
Cisplatin treatment of MPTC. MPTC monolayers reached confluence within 6 days and were treated with cisplatin on day 7 of culture. Samples of MPTC were taken at various time points (between 4 and 18 h) of cisplatin exposure. Caspase inhibitors DEVD-fmk and Z-VAD-fmk were added 0.5 h before cisplatin treatment. Control MPTC were treated with diluent (DMSO; 0.1% final concentration).
Measurement of caspase activities. Caspase-3-, caspase-8-, and caspase-9-like activities were quantified by fluorometric detection of AFC after cleavage from DEVD-AFC, IETD-AFC, and LEHD-AFC, respectively. In brief, media were aspirated from culture dishes, MPTC monolayers were washed twice with ice-cold PBS, scraped from the culture dishes, resuspended and lysed in cell lysis buffer (10 min on ice, BioVision, Palo Alto, CA), and centrifuged at 15,000 g for 10 min at 4°C. The pellet was discarded, and the supernatant was used for caspase assays. The supernatant samples were incubated for 1 h at 37°C in the presence of the reaction buffer optimized for caspase activity assays (BioVision), 10 mM dithiothreitol, and 50 M DEVD-AFC (for measurements of caspase-3-like activity), 50 M IETD-AFC (for measurement of caspase-8-like activity), or 50 M LEHD-AFC (for measurement of caspase-9-like activity). The samples were read in a fluorometer at 380/500 nm (excitation/emission), and the amount of product cleaved under linear conditions was determined from the AFC standard curve.
Immunoblotting. Immunoblot analysis was used for the measurement of protein levels of p21 and cleaved (active) caspase-3, caspase-8, and caspase-9 in renal proximal tubular cell homogenates. Renal proximal tubular cell homogenates were lysed and boiled for 10 min in Laemmli sample buffer (60 mM Tris ⅐ HCl, pH 6.8, containing 2% SDS, 10% glycerol, 100 mM ␤-mercaptoethanol, and 0.01% bromophenol blue) (18) , and proteins were separated using SDS-PAGE. Following electroblotting of the proteins to a nitrocellulose membrane, blots were blocked for 1 h in 50 mM Tris-buffered saline (pH 7.5) containing 0.5% casein and 0.1% Tween 20 (blocking buffer) and incubated overnight at 4°C in the presence of primary antibodies diluted in the blocking buffer. Following washing with 50 mM Tris-buffered saline containing 0.05% Tween 20, the membranes were incubated for 1 h with anti-rabbit or anti-mouse IgG coupled to horseradish peroxidase and washed again. The supersignal chemiluminescent system (Pierce, Rockford, IL) was used for protein detection, and scanning densitometry was utilized for the quantification of results.
Assessment of oncosis. The release of LDH into the culture medium was measured as a marker of oncosis, as described previously (31) . Oncosis was also assessed by measuring the permeability of the MPTC plasma membrane to ethidium homodimer. As plasma membrane permeability increases, ethidium homodimer enters the cell and binds to DNA, producing a bright red fluorescence. After 24 h of cisplatin exposure, MPTC monolayers were incubated with 25 M ethidium homodimer for 15 min on ice, and cells were processed for fluorescence analysis. In brief, media were aspirated and MPTC were scraped from the culture dishes, washed twice with ice-cold PBS, and resuspended in PBS. Cell-associated fluorescence was analyzed by flow cytometry (BD FACSCalibur) using excitation at 488 nm and emission at 590 nm. For each sample, 10,000 events were counted.
Assessment of apoptosis. Apoptosis was assessed using two dissimilar markers: plasma membrane phosphatidylserine externalization measured by annexin V/propidium iodide binding assay and chromatin condensation and nuclear fragmentation measured by immunocytochemistry. MPTC were washed twice with a binding buffer consisting of (in mM) 10 HEPES (pH 7.4), 140 NaCl, 5 KCl, 1 MgCl2, and 1.8 CaCl2. Following resuspension in the binding buffer, MPTC were incubated in the presence of propidium iodide (2 g/ml) for 15 min on ice, washed three times with the binding buffer, and incubated in the presence of annexin V-FITC (125 ng/ml) for 10 min at room temperature. MPTC were washed three times with the binding buffer and processed for flow cytometry. Propidium iodide and annexin V-FITC fluorescence was quantified by flow cytometry using excitation at 488 nm and emission at 590 and 530 nm for propidium iodide and annexin V-FITC, respectively. For each sample, 10,000 events were counted. Cells positive for annexin V and negative for propidium iodide were considered apoptotic.
MPTC nuclei were visualized by DAPI staining. The monolayers were fixed in 3.7% formaldehyde for 15 min, rinsed with PBS, and incubated with 8 M DAPI for 2 h at room temperature. Following staining, MPTC monolayers were washed with PBS, coverslips were applied, and nuclei were evaluated using a Zeiss fluorescent microscope (Axioscope). Total and condensed or fragmented nuclei were counted in six to eight different areas of every monolayer using two plates per each experimental group from three independent MPTC isolations.
Biochemical assays. Protein concentration was determined using bicinchoninic acid assay and bovine serum albumin as the standard. Cellular DNA content was determined using a PicoGreen dsDNA Quantitation Kit (Molecular Probes). Monolayers were solubilized in 0.1 M Tris ⅐ HCl (pH 7.4) containing 0.15 M NaCl and 0.05% Triton X-100, and DNA was determined in cell lysates according to the manufacturer's protocol.
Statistical analysis. Data are presented as means Ϯ SE and were analyzed for significance using ANOVA. Multiple means were compared using the Student-Newman-Keuls test. Statements of significance were based on P Ͻ 0.05. Murine renal proximal tubules isolated on a given day represent a separate experiment (n ϭ 1) consisting of data obtained from two plates.
RESULTS
Metabolic characteristics of primary cultures of
MPTC grown in optimized culture conditions. Previously, we showed that primary cultures of rabbit renal proximal tubular cells maintain many in vivo differentiated functions of renal proximal tubules when grown under optimized culture conditions (33, 34). Improving culture media oxygenation (by shaking the dishes) in conjunction with decreasing glucose concentration and supplementing with lactate and ascorbic acid results in a reduction in glycolysis, an in vivo-like respiration, and an increase in transport functions. Therefore, we modified the original culture conditions (33) used to grow MPTC in primary culture to improve the growth, oxidative metabolism, and transport functions in these cells. The modifications included 1) decreasing glucose concentration in the culture media from 5 to 1 mM, 2) supplementing media with 5 mM lactate (a major substrate for the kidney in vivo) and 50 M ascorbic acid phosphate, and 3) shaking the dishes to improve media oxygenation.
Protein and DNA contents of confluent MPTC monolayers grown in the improved culture conditions are illustrated in Table 1 . Basal and uncoupled QO 2 were used as markers of oxidative metabolism and electron transport through the respiratory chain, respectively ( (30) . Na ϩ -dependent glucose uptake was measured using a nonmetabolizable glucose analog MGP. MGP uptake in confluent quiescent MPTC (Table 1 ) was similar to MGP uptake in primary cultures of rabbit renal proximal tubular cells (34) . Phlorizin (1 mM) inhibited MGP uptake in MPTC by 97 Ϯ 1%. Cellular density, respiration, active Na ϩ transport, and Na ϩ -dependent glucose uptake in MPTC isolated from mice lacking p21 WAF1/CIP1 were equivalent to those in MPTC from p21(ϩ/ϩ) mice (Table 1 ). These data show that primary cultures of MPTC grown in optimized conditions maintain in vivo-like respiration and active Na ϩ transport of renal proximal tubules in the presence and absence of p21 WAF1/CIP1
.
Cisplatin exposure and p21
WAF1/CIP1 protein levels. Protein levels of p21 WAF1/CIP1 in MPTC from p21(ϩ/ϩ) mice increased twofold at 4 h of exposure to 15 M cisplatin and remained increased until the end of the treatment (18 h) (Fig. 1A) . Caspase inhibitors had no effect on cisplatin-induced increases in p21 levels (Fig.  1A) . p21 WAF1/CIP1 protein was absent in control and cisplatin-treated MPTC from p21(Ϫ/Ϫ) mice (Fig. 1B) .
Cisplatin-induced caspase activation in p21(ϩ/ϩ) MPTC. Caspase activation in MPTC was assessed by measuring caspase activities and evaluating the formation of caspase cleavage products during cisplatin exposure.
Caspase-3, caspase-8, and caspase-9 activities were assessed in MPTC after cisplatin (5, 10, and 15 M) exposure and in MPTC treated with the vehicle (0.1% DMSO, controls). No significant changes in caspase-3 activity were observed in MPTC treated with DMSO. Caspase-3 activity was not altered during the first 8 h of cisplatin treatment in MPTC ( Fig. 2A) . At 12 h, caspase-3 activity was unaffected in MPTC treated with 5 and 10 M cisplatin but increased fivefold in MPTC incubated with 15 M cisplatin ( Fig. 2A) . At 18 h, caspase-3 activity increased 11-fold in MPTC incubated with 10 M cisplatin and was 22-fold higher in MPTC treated with 15 M cisplatin ( Fig. 2A) . Immunoblot analysis showed the presence of significant amounts of the cleaved (active) caspase-3 (17-20 kDa) in MPTC treated with 15 M cisplatin for 18 h (Fig.  2C) . The caspase inhibitors DEVD-fmk and ZVAD-fmk decreased caspase-3 processing during 15 M cisplatin exposure (Fig. 2C) .
To elucidate whether caspase-8 and caspase-9 play a role in cisplatin-induced caspase-3 activation in MPTC, we examined the time course of the activation of caspase-8 and caspase-9 during cisplatin exposure compared with the activation of caspase-3. There was no significant change in caspase-8 activity during 12 h of exposure at any concentration of cisplatin, whereas caspase-3 activity was markedly increased (Figs. 2A  and 3A ). Cisplatin at 10 and 15 M increased caspase-8 activity two-and threefold, respectively, after 18 h of treatment (Fig. 3A) . Nevertheless, immunoblot analysis showed no cleavage products of caspase-8 (10 kDa) in MPTC exposed to 15 M cisplatin for 18 h (Fig. 3C) . These results show that caspase-8 activation either does not occur in cisplatin-treated MPTC or caspase-8 activation by cisplatin is minor and follows caspase-3 activation.
No activation of caspase-9 occurred during an 18-h exposure of MPTC to 5 and 10 M cisplatin (Fig. 4A ). An 18-h treatment with 15 M cisplatin increased MPTC caspase-9 activity 2.3-fold (Fig. 4A) . However, immunoblot analysis demonstrated only the presence of procaspase-9 (47 kDa) and no cleaved caspase-9 (35 and 37 kDa) in MPTC exposed to 15 M cisplatin for 18 h (Fig. 4C) . Based on the caspase activity and immunblot assays, we conclude that cisplatin activates caspase-3 without activation of caspase-9 and caspase-8 in p21(ϩ/ϩ) MPTC.
Cisplatin-induced caspase activation in p21(Ϫ/Ϫ) MPTC. Exposure to 15 M cisplatin for 8 h resulted in a threefold increase in caspase-3 activity in p21(Ϫ/Ϫ) MPTC, whereas no activation of caspase-3 occurred at this time point in p21(ϩ/ϩ) MPTC (Fig. 2, A and B) . At 12 h of treatment, caspase-3 activity increased fourfold and sixfold in the presence of 10 and 15 M cisplatin, respectively (Fig. 2B) . Caspase-3 activity continued to increase and, at 18 h of exposure, was 14-fold higher in cells treated with 15 M cisplatin than in controls and was threefold higher than in p21(ϩ/ϩ) MPTC (Fig. 2, A  and B) . Immunoblot analysis demonstrated the pres- ence of the cleaved form of caspase-3 at 12 h of 15 M cisplatin exposure in p21(Ϫ/Ϫ) MPTC and a further increase in protein levels of the active caspase-3 at 18 h of cisplatin treatment (Fig. 2D) . Similar to p21(ϩ/ϩ) MPTC, the caspase inhibitors DEVD-fmk and ZVADfmk decreased caspase-3 cleavage during cisplatin exposure in p21(Ϫ/Ϫ) MPTC (Fig. 2D) .
No increase in caspase-8 activity was observed in p21(Ϫ/Ϫ) MPTC during the first 8 h of cisplatin treatment (Fig. 3B) . After 12 h of exposure to 15 M cisplatin, caspase-8 activity increased threefold in p21(Ϫ/Ϫ) MPTC, whereas no activation of caspase-8 occurred in p21(ϩ/ϩ) MPTC at this time point (Fig. 3, A and B) . At 18 h of treatment, caspase-8 activity in p21(Ϫ/Ϫ) MPTC treated with 15 M cisplatin was fourfold higher than in respective controls and threefold higher than in p21(ϩ/ϩ) MPTC undergoing the same treatment (Fig. 3, A and B) . However, immunoblot analysis showed no cleaved (active) form of caspase-8 in p21(Ϫ/Ϫ) MPTC exposed to 15 M cisplatin for 18 h (Fig. 3D) .
No increase in caspase-9 activity occurred during the first 8 h of cisplatin treatment in p21(Ϫ/Ϫ) MPTC (Fig.  4B) . After 12 h of cisplatin (15 M) exposure, caspase-9 activity increased sevenfold in p21(Ϫ/Ϫ) MPTC, whereas no increase in caspase-9 activity occurred in p21(ϩ/ϩ) MPTC (Fig. 4, A and B) . At 18 h of treatment, caspase-9 activity in p21(Ϫ/Ϫ) MPTC treated with 15 M cisplatin was eightfold higher than in controls and twofold higher than in p21(ϩ/ϩ) MPTC undergoing the same treatment (Fig. 4, A and B) . In contrast to p21(ϩ/ϩ) MPTC, immunoblot analysis demonstrated the presence of cleaved forms of caspase-9 (35 and 37 kDA) in p21 (Ϫ/Ϫ) MPTC starting at 4 h of the cisplatin exposure (Fig. 4D) . The caspase inhibitors DEVD-fmk and ZVAD-fmk did not block cisplatin-induced caspase-9 processing in p21(Ϫ/Ϫ) MPTC (Fig. 4D ). These results demonstrate that the lack of p21 WAF1/CIP1 results in the acceleration and greater extent of activation of caspase-3 and the activation caspase-9 by cisplatin.
Assessment of cisplatin-induced MPTC apoptosis by annexin V/propidium iodide binding. Cisplatin-induced MPTC apoptosis was assessed using annexin V binding as a marker of phosphatidylserine externalization. Cisplatin (15 M) induced 18 Ϯ 6 and 25 Ϯ 9% apoptosis in p21(ϩ/ϩ) MPTC at 12 and 18 h of exposure, respectively (Fig. 5A) . The caspase inhibitors DEVD-fmk and ZVAD-fmk had no effect on the number of annexin V-positive cells at 12 or 18 h of cisplatin exposure (Fig. 5A) . These results suggest that caspase inhibition does not block cisplatin-induced apoptosis in MPTC.
Annexin V binding in p21(Ϫ/Ϫ) MPTC was 26 Ϯ 9 and 30 Ϯ 9% at 12 and 18 h of cisplatin treatment, respectively, and was caspase inhibitor independent (Fig. 5B) . Furthermore, the apoptosis in control p21(Ϫ/Ϫ) MPTC (i.e., spontaneous apoptosis) was increased 1.4-fold at both 12-and 18-h time points compared with control p21(ϩ/ϩ) MPTC (Fig. 5) . These results show that the lack of p21 accelerates cisplatininduced caspase-independent apoptosis in MPTC.
LDH release was 4 Ϯ 2% in p21(ϩ/ϩ) MPTC and 4 Ϯ 1% in p21(Ϫ/Ϫ) MPTC after 24 h of cisplatin (15 M) exposure and was not different from LDH release in controls (1 Ϯ 1%). Uptake of ethidium homodimer in MPTC treated with 15 M cisplatin for 24 h (4 Ϯ 1%) was not different from that in controls (3 Ϯ 1%). These results show that the plasma membrane was not compromised by cisplatin exposure and support the conclusion that cisplatin induced apoptosis in MPTC in the absence of oncosis.
Assessment of cisplatin-induced MPTC chromatin condensation and nuclear fragmentation. In p21(ϩ/ϩ) MPTC, nuclear changes occurred in 32 Ϯ 1% of the cells treated with 15 M cisplatin for 18 h (Figs. 6B  and 7A ), an amount significantly greater (45 Ϯ 2%) than in p21(Ϫ/Ϫ) MPTC (Figs. 6F and 7B ). Monolayers pretreated with DEVD-fmk or 50 M ZVAD-fmk before cisplatin (15 M) treatment and caspase activities and chromatin condensation were assessed after 18 h of exposure. DEVD-fmk and ZVAD-fmk prevented the increase in caspase-3 activity and procaspase-3 cleavage in cisplatin-treated MPTC regardless of the presence or absence of p21 WAF1/CIP1 (Fig. 2, A and B) . Similarly, ZVAD-fmk and DEVD-fmk abolished cisplatin-induced increases in LEHD-ase (Fig. 4, A and B) and IETD-ase (Fig. 3, A and B) activities in both p21(ϩ/ϩ) and p21(Ϫ/Ϫ) MPTC. However, neither DEVD-fmk nor ZVAD-fmk blocked procaspase-9 processing in p21(Ϫ/Ϫ) MPTC treated with cisplatin (Fig.  4D) . These data suggest that blocking caspase-3 activation in cisplatin-treated MPTC prevents increases in caspase-8 and caspase-9 activities and support our conclusion that increases in caspase-8-like and caspase-9-like activities are secondary to caspase-3 activation.
Treatment of MPTC with DEVD-fmk and ZVAD-fmk for 18 h had no effect on nuclear morphology in control MPTC (Figs. 5, A and B, and 7, A and B) . Pretreatment of p21(ϩ/ϩ) MPTC with DEVD-fmk or ZVAD-fmk before cisplatin exposure had no effect on the number of cells with chromatin condensation and nuclear fragmentation (Figs. 6, C and D, and 7A) . Similarly, pretreatment with both inhibitors did not prevent cisplatin-induced MPTC shrinkage and detachment from the monolayer (data not shown). These data suggest that cisplatin-induced apoptosis in p21(ϩ/ϩ) MPTC is caspase independent.
Pretreatment of p21(Ϫ/Ϫ) MPTC with DEVD-fmk had no significant effect on cisplatin-induced chromatin condensation and nuclear fragmentation despite the decrease in caspase-3 processing and complete inhibition of caspase-3 activity (Figs. 2, B and D, 6G , and 7B). However, pretreatment with ZVAD-fmk before cisplatin exposure decreased nuclear condensation in p21(Ϫ/Ϫ) MPTC ϳ51% at 18 h (Figs. 6H and 7B) . These results suggest that, in addition to caspaseindependent apoptosis, another mechanism(s) is responsible for the increased cisplatin sensitivity of p21(Ϫ/Ϫ) MPTC. The other mechanism is caspase dependent, but the pathway is independent of caspase-3, -8, and -9 activation.
DISCUSSION
ARF after ischemia or cisplatin administration is associated with a rapid induction of the cell cycle inhibitory protein p21 WAF1/CIP1 gene and overexpression of p21 WAF1/CIP1 protein (26, 29) . p21 WAF1/CIP1 induction is associated with cell-cycle interruption and arrest in the G 1 phase of the cell cycle (46) . Induction of p21
after cisplatin administration has a protective effect on the murine kidney as mice lacking p21 WAF1/CIP1 display a more rapid onset of ARF and have a higher mortality rate than wild-type animals (27) . The proximal tubule segment of the nephron is the most sensitive to cisplatin and undergoes severe damage in response to cisplatin-based chemotherapy (10) . In vivo studies demonstrated that proximal tubular cells in mice lacking p21 WAF1/CIP1 exhibited greater cell death than proximal tubular cells in wild-type mice (28) . Our in vitro studies show that low concentrations of cisplatin cause cell death by apoptosis, but not oncosis, and that the lack of p21 WAF1/CIP1 increases the extent of apoptosis by 40% in primary cultures of MPTC. Thus our results suggest that p21 WAF1/CIP1 plays a protective role by decreasing cisplatin-induced cell death. Furthermore, our data demonstrate that the increase in apoptosis in mice lacking p21 WAF1/CIP1 is the result of a direct effect of cisplatin on the renal proximal tubular cells.
The lack of p21 WAF1/CIP1 is associated with the acceleration of caspase activation and apoptosis. Caspase proteases play an important role in apoptosis by degrading specific structural, regulatory, and DNA repair proteins within the cell. Caspase-3 is one of the key executioners of apoptosis and is responsible for the proteolytic cleavage of proteins essential for cell survival. The best known pathways of caspase-3 activation are those through proteolytic cleavage of the caspase-3-inactive zymogen by initiator caspases, caspase-8 and caspase-9. Caspase-8 is recruited after activation of receptors belonging to a family of "death receptors." Caspase-9 is activated as a result of mitochondrial dysfunction and release of cytochrome c from the mitochondrial intermembrane space. Activated caspase-8 and caspase-9 initiate the proteolytic activity of other downstream caspases, including caspase-3 and caspase-6. Therefore, the activation of caspase-8 or caspase-9 precedes activation of caspase-3 during caspase-8-or caspase-9-initiated apoptosis. While cisplatin-induced apoptosis in MPTC is associated with activation of caspase-3, caspase-8 is not cleaved to the enzymatically active form despite increases in IETDase activity that accompany apoptosis in MPTC in the presence or absence of p21 WAF1/CIP1 . Therefore, we conclude that 1) the increases in IETD-ase activity were not due to caspase-8, 2) caspase-8 is not activated by cisplatin in MPTC, and 3) caspase-3 is not activated by caspase-8.
Similarly, our data show that caspase-9 was not processed to the active form in p21(ϩ/ϩ) MPTC treated with cisplatin. Therefore, the increases in LEHD-ase activity at 18 h of cisplatin exposure were not due to caspase-9 activation and caspase-3 activation occurred without caspase-9. In contrast, caspase-9 was cleaved in cisplatin-treated p21(Ϫ/Ϫ) MPTC and caspase-9 processing preceded caspase-3 activation. These results suggest the sequential activation of caspase-9 and caspase-3 in p21(Ϫ/Ϫ) MPTC but not in p21(ϩ/ϩ) MPTC after cisplatin exposure. These data are somewhat in contrast to the results of Kaushal and colleagues (14) , who demonstrated the activation of caspase-8, caspase-9, and caspase-3 by cisplatin in LLC-PK 1 cells. This discrepancy may be due to differences between immortalized cell lines and primary cultures, including differences in cellular metabolism. It is also possible that caspase-8 and caspase-9 in wild-type MPTC are activated late during cisplatininduced apoptosis (Ͼ18 h of exposure). However, similar to our results, Kaushal et al. reported that the activation of caspase-3 preceded that of caspase-8 and caspase-9 and concluded that caspase-3 activation may be initiated by a caspase-independent pathway or caspases other than caspase-8 and caspase-9.
Our results suggest that caspase-3 activation by cisplatin in MPTC may be partially regulated through a p21 WAF1/CIP1 -dependent mechanism because the lack of functional p21 WAF1/CIP1 protein accelerates caspase-3 activation. This is in agreement with reports that p21 WAF1/CIP1 overexpression suppresses caspase activation and apoptosis (47, 48) . However, despite caspase-3 activation during cisplatin-induced apoptosis, caspase-3 does not appear to be involved in the execution of apoptosis in either p21(ϩ/ϩ) MPTC or p21(Ϫ/Ϫ) MPTC. This conclusion is based on the observation that a caspase-3 inhibitor, DEVD-fmk, blocked caspase-3 activation but did not prevent MPTC phosphatidylserine externalization, chromatin condensation, and cell shrinkage (Figs. 5 and 7; data not shown). Therefore, we conclude that caspase-3 is activated by cisplatin but is not required for cisplatininduced apoptosis in MPTC. Caspase-3-independent apoptosis has been reported in other models, including X-irradiation-induced apoptosis in rat embryonic fibroblasts (16) and cisplatin-induced apoptosis in rabbit primary cultures of renal proximal tubular cells (4, 32) . Furthermore, genetic deletion of caspase-3 and caspase-9 does not alter apoptosis during embryogenesis and fetal development in mice, further supporting the existence of caspase-3-and caspase-9-independent mechanisms of apoptosis (35) . Apoptosis induced by a variety of stimuli in human breast cancer MCF-7 cells bypasses the need for caspase-3 activation and pro- 
